Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Researcher And U.S. Team Find Drug Target For Schizophrenia 

This article was originally published in PharmAsia News

Executive Summary

Chief Researcher Mitsuyuki Matsumoto of Tokyo-based Astellas Pharma and a research team from the U.S. National Institutes of Mental Health found a protein that leads to the onset of schizophrenia symptoms including loss of memory and movement disorder. The protein SERB2 was discovered through pharmaceutical research on human and animal genomes. Recent testing on mice found that a genetically modified mouse with surplus amounts of SREB2 was found to develop a lighter weight brain, slower movement and lower information processing ability. NIMH team analyzed DNA samples of schizophrenia patients and further confirmed the role of SREB2 as the disease susceptibility gene. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel